EVERSANA partners Oracle on pharmacovigilance platform

EVERSANA has signed an agreement with Oracle Argus Cloud to add to the features of its pharmacovigilance platform, which helps manufacturers monitor drug safety in an increasingly complex pharmaceutical market.

The partnership has added new functionality to the pharmacovigilance platform, including artificial intelligence-enabled automation, workflow optimisation, and conditional touchless processing which can reduce the manual intervention needed to monitor adverse effects of medicines.

The refinements to its offering are designed to lighten the load of medical affairs teams as they face "increasing caseloads and changing regulations across the life sciences industry," said pharmaphorum parent EVERSANA in a statement.

The move ties in with the trend in the industry for pharmacovigilance to shift from a reactive activity – which can be plagued by inconsistent reporting – to one based on proactive monitoring.

According to the company, several of its pharmacovigilance customers have transitioned to the platform, which it claims can speed up case processing and reduce costs per case by around 50%.

The alliance also means that EVERSANA will now be "promoted by Oracle to global customers for our pharmacovigilance and implementation services," it said in a statement.

"We believe that pharmacovigilance services across the life sciences industry are powered by innovation and transformational thinking," said Jim Lang, EVERSANA's chief executive.

"Together with Oracle’s leading systems, we are doing just this, combining our experience and operational excellence with best-in-class systems to drive better outcomes and put patient safety first."

Patient support goes global

In related news, the company has expanded its global medical information contact centre capabilities with multi-language and around-the-clock support across four regional hubs including North America, Europe, India and Japan.

Trained experts are available to answer calls from clinicians, patients, and caregivers in their native language to ensure they have the latest information on therapy and can report any adverse effects or product complaints.

"Today’s drug safety industry demands that service providers deliver critical medical information to doctors and patients in their region and at any time," remarked Lang.

"Our investments in global experts top talent and transformational technology will help bring this commitment to life."